BT8009

Other Medications

Description

BT8009 is an investigational drug currently being studied in clinical trials for certain types of advanced cancer. It is being evaluated for its safety and effectiveness, both alone and in combination with pembrolizumab (an immunotherapy drug). The trials are looking at different doses and schedules to find the best way to use it. BT8009 is being studied in patients whose tumors express Nectin-4. This is a Phase 1 trial, meaning the main goal is to determine the safest dose and see if the drug has any activity against the cancer. It is not yet approved for use in colorectal cancer or any other cancer.

Mechanism of Action

BT8009 is designed to target Nectin-4, a protein found on the surface of some cancer cells. By binding to Nectin-4, BT8009 aims to deliver a toxic substance (MMAE) directly into the cancer cells, potentially leading to their death. The specific mechanism is being investigated in clinical trials.

Side Effects

As BT8009 is an investigational drug in early-phase trials (Phase 1) The full range of potential side effects is still being evaluated. The primary focus of Phase 1 trials is to assess safety and tolerability. Common side effects seen in early trials of similar drugs can include fatigue Nausea And changes in blood counts But specific data for BT8009 is limited. More information will become available as clinical trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04561362 Phase 1

Active, not recruiting

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

United States, Canada, France, Italy, Spain, United Kingdom

Quick Info

Category	Other Medications
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.